PaxMedica, Inc. (PXMD)

PaxMedica will go public soon, but the exact IPO date is still unknown.

Stock Price: $5.50 - $6.50

Current IPO price range

Stock Price Chart

Key Info

Market Cap	59.88M
Revenue (ttm)	n/a
Net Income (ttm)	-2.15M
Shares Out	9.98M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	n/a
Last Price	$n/a
Previous Close	$n/a
Change ($)	n/a
Change (%)	n/a
Day's Open	n/a
Day's Range	n/a - n/a
Day's Volume	n/a
52-Week Range	n/a - n/a

More Stats

Market Cap	59.88M
Enterprise Value	n/a
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	9.98M
Float	n/a
EPS (basic)	n/a
EPS (diluted)	-0.22
FCF / Share	n/a

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	n/a
Short Ratio	n/a
Short % of Float	n/a
Beta	n/a

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	n/a
Revenue	n/a
Operating Income	n/a
Net Income	-2.15M
Free Cash Flow	n/a

Net Cash	n/a
Net Cash / Share	n/a
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	n/a
ROE	n/a
ROIC	n/a

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy	0
Overweight	0
Hold	0
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: n/a

Price Target

$n/a*

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in USD.

Financial Overview

Year	2019	2018
Revenue	0	0
Net Income / Loss	-598,609	-222,279

Numbers in USD.

Company Profile

Company Details

Full Name	PaxMedica, Inc.
Country	United States
Employees	4
CEO	Howard J. Weisman

Stock Information

Ticker Symbol	PXMD
Stock Exchange	NASDAQ
Unique Identifier	NASDAQ: PXMD
IPO Date	Pending

Description

PaxMedica is an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells.